HemoSonics appoints Josep Manent to Board of Managers

Former CEO of Instrumentation Laboratory Adds Depth to Board

Charlottesville, VA – September 17, 2015 – HemoSonics, a medical device company developing and commercializing a point-of-care diagnostic platform to guide the management of critical bleeding in surgery and acute care settings, announced that Josep Manent has been elected to its Board of Managers.

Mr. Manent has over 35 years of business, financial, product development and marketing experience in the in vitro diagnostics (IVD) industry.  He previously held senior management positions in the Werfen Life Group, a family of leading companies in the IVD sector. Most recently, he served as the CEO of Instrumentation Laboratory (IL), a leader in critical care, hemostasis and point-of-care diagnostics, from 1999 until his retirement in 2011.  Under his leadership at IL, the company returned to profitability and became a world leader in hemostasis and point-of-care through a combination of creative customer targeting, efficient manufacturing and a focus on innovative product development.

“Josep brings an unparalleled depth of experience and industry knowledge in the in vitro diagnostics space,” said William P. Moffitt, Chairman of the Board of HemoSonics. “His perspective, global reputation and insight will be invaluable as we initiate commercialization of the Quantra™ platform and seek to accelerate shareholder value.”

Prior to his employment with Werfen, Mr. Manent was a co-founder of Biokit, a developer of systems and immunoassay tests for clinical laboratories, and served as its President and General Manager for 20 years.  Biokit was acquired by Werfen. Mr. Manent received his MBA at ESADE Business School and participated in Executive and Marketing programs at Stanford University.

“I believe HemoSonics has a unique product that will revolutionize the point-of-care hemostasis testing market in the critical care setting,” said Mr. Manent. “As a Board member, I look forward to supporting the Company as we prepare for registration and commercialization of the Quantra™ System.”

About HemoSonics

HemoSonics is a medical device company with the goal of improving outcomes and reducing healthcare costs by enabling more targeted selection and dosing of blood products in critical care settings. The company is developing the Quantra™, a point-of-care in vitro diagnostic platform that measures blood clot formation and breakdown and provides actionable information to guide the management of critical bleeding and clotting. HemoSonics seeks to transform the way clinicians manage coagulation dysfunctions by providing comprehensive, timely and accurate information on coagulation status at the point of care, enabling clinicians to rapidly choose the right treatment. HemoSonics’ products are for Research Use Only and are not intended for clinical diagnostic use at the current time. For more information, visit http://hemosonics.com.

###

Contact

Megan Shaw

VP Marketing and Business Development

434.260.0682

contact@hemosonics.com